Burkina Faso vs Nigeria: Share of the population living with HIV receiving antiretroviral therapy
Burkina Faso
82.0%
in 2024
Nigeria
83.3%
in 2024
Burkina Faso rank
46th
Nigeria rank
44th
Share of the population living with HIV receiving antiretroviral therapy over time
- Burkina Faso
- Nigeria
How they compare
Nigeria currently reports 83.3% against 82.0% in Burkina Faso, a difference of 1.3%.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Nigeria ahead.
Burkina Faso ranks 46th and Nigeria ranks 44th of 149 countries.
Burkina Faso has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Burkina Faso | Nigeria | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 7.9% | 5.0% | 2.9% | Burkina Faso |
| 2010s | 49.8% | 35.6% | 14.2% | Burkina Faso |
| 2020s | 74.8% | 70.8% | 4.1% | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Burkina Faso or Nigeria?
- Nigeria, at 83.3% against 82.0% in Burkina Faso as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Burkina Faso and Nigeria?
- 1.3%, with Nigeria ahead.
- How many years of comparable data are there for Burkina Faso and Nigeria?
- 35 years are reported by both, from 1990 to 2024.
- How do Burkina Faso and Nigeria rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Burkina Faso ranks 46th and Nigeria ranks 44th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.